Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Ian Hodgson, PhD +1 (617) 963-0105
Clinical@Corbuspharma.com


Rodney Carter, BSc Clinical@Corbuspharma.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Back

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Recruiting

Open to: ALL

Age: 18.0 - N/A

Southampton Manchester Birmingham London London Cambridge Cardiff Leeds Metropolitan Borough of Wirral

Medical Conditions

Solid Tumor, Adult

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.

The main questions it aims to answer are:

What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701?

Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2024 Jan 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Nectin-4 targeted Antibody Drug Conjugate (ADC)

Intervention Arm Group : Part A Dose Escalation - CRB-701 Dose Level 1;Part A Dose Escalation - CRB-701 Dose Level 2;Part A Dose Escalation - CRB-701 Dose Level 3;Part A Dose Escalation - CRB-701 Dose Level 4;Part B Dose Optimization: CRB-701 High dose;Part B Dose Optimization: CRB-701 high dose combined with anti-PD-1;Part B Dose Optimization: CRB-701 low dose;Part B Dose Optimization: CRB-701 low dose combined with anti-PD-1;Part C Dose Expansion - Cohort 1;Part C Dose Expansion - Cohort 2;Part C Dose Expansion - Cohort 3;Part C Dose Expansion - Cohort 4;Part C Dose Expansion - Cohort 5;Part C Dose Expansion - Cohort 6;Part C Dose Expansion - Cohort 7;

Intervention Type : DRUG
Intervention Description : checkpoint inhibitor

Intervention Arm Group : Part B Dose Optimization: CRB-701 high dose combined with anti-PD-1;Part B Dose Optimization: CRB-701 low dose combined with anti-PD-1;Part C Dose Expansion - Cohort 1;Part C Dose Expansion - Cohort 3;Part C Dose Expansion - Cohort 5;Part C Dose Expansion - Cohort 7;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University of Southampton
    Southampton
    SO16 6YD
  • The Christie Hospital
    Manchester
    M20 4BX
  • University of Birmingham NHS Foundation Trust
    Birmingham
    B15 2TH
  • Guy's and St Thomas' Clinical Research Facility
    London
    SE1 9RT
  • Imperial Experimental Cancer Medicine Centre
    London
    W12 0NN
  • University of Cambridge NHS Foundation Trust
    Cambridge
    CB2 0QQ
  • Velindre Cancer Centre
    Cardiff
    CF15 7QZ
  • Leeds University Hospitals NHS Trust
    Leeds
    LS9 7LP
  • University of Liverpool - Clatterbridge Medical Centre
    Metropolitan Borough of Wirral
    CH63 4JY

Rodney Carter, BSc Clinical@Corbuspharma.com


Ian Hodgson, PhD +1 (617) 963-0105
Clinical@Corbuspharma.com



The study is sponsored by Corbus Pharmaceuticals Inc. and is in collaboration with CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd..



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06265727
Last updated 07 January 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top